Correlation Engine 2.0
Clear Search sequence regions


  • BCL2 (33)
  • CREBBP (2)
  • EP300 (2)
  • EP400 (1)
  • exons (1)
  • EZH2 (3)
  • female (1)
  • follicular lymphoma (6)
  • genes (3)
  • humans (1)
  • immunoglobulin (1)
  • minor (1)
  • MLL2 (2)
  • MLL3 (2)
  • oncogenes (1)
  • oncogenesis (1)
  • patients (1)
  • protein human (1)
  • TET2 (1)
  • tFLs (7)
  • thyroid (5)
  • tumour suppressor genes (1)
  • Sizes of these terms reflect their relevance to your search.

    Follicular lymphoma (FL), comprising a minor subset of primary thyroid lymphomas, is divided into two groups based on Bcl-2 expression and IGH-BCL2 translocation. The clinicopathological features exhibited by Bcl-2-negative IGH-BCL2 translocation-negative FL of the thyroid (Bcl-2- /IGH-BCL2- tFL) are different from those of conventional FL; however, its lymphomagenesis remains unclear. Here, we collected samples from seven patients with Bcl-2- /IGH-BCL2- tFL to investigate their epigenetic and genetic aberrations. The immunohistochemical profiles of epigenetic modifiers and the methylation status of histones were examined, including EZH2, MLL2/KMT2D, CBP/CREBBP, EP300, H3K27me3 and H3K4me3, in Bcl-2- /IGH-BCL2- tFL and Bcl-2-positive IGH-BCL2 translocation-positive FL of the thyroid (Bcl-2+ /IGH-BCL2+ tFL). Most Bcl-2- /IGH-BCL2- tFLs retained the positivity of epigenetic modifiers and lower expression of H3K27me3, although Bcl-2+ /IGH-BCL2+ tFLs exhibited aberrant immunohistochemical patterns of EZH2 and CBP/CREBBP and overexpression of H3K27me3. Samples from seven cases were further analysed using targeted sequencing, focusing on the exons of 409 key tumour suppressor genes and oncogenes. Bcl-2- /IGH-BCL2- tFLs do not have pathogenic mutations of epigenetic modifiers, such as EZH2, MLL2/KMT2D, MLL3/KMT2C, EP300 and ARID1A, which have been reported in FLs in the literature, whereas Bcl-2+ /IGH-BCL2+ tFLs are probably pathogenic/pathogenic missense mutations or frameshift mutations of these genes. Additionally, novel mutations in TET2 and EP400 were detected in Bcl-2- /IGH-BCL2- tFLs. Different genetic and epigenetic abnormalities might be involved in the oncogenesis of Bcl-2- /IGH-BCL2- tFLs from Bcl-2+ /IGH-BCL2+ tFLs and other FLs. © 2021 John Wiley & Sons Ltd.

    Citation

    Yuichiro Hamamoto, Yoji Kukita, Masanori Kitamura, Masako Kurashige, Hiroaki Masaie, Shigeo Fuji, Jun Ishikawa, Keiichiro Honma, Tomoko Wakasa, Hitoshi Hanamoto, Mitsuyoshi Hirokawa, Ayana Suzuki, Eiichi Morii, Shin-Ichi Nakatsuka. Bcl-2-negative IGH-BCL2 translocation-negative follicular lymphoma of the thyroid differs genetically and epigenetically from Bcl-2-positive IGH-BCL2 translocation-positive follicular lymphoma. Histopathology. 2021 Oct;79(4):521-532

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 33829512

    View Full Text